Category

NASDAQ

Jupiter Wellness Acquisition Corp. to Extend Period to Consummate Initial Business Combination NASDAQ

Jupiter Wellness Acquisition Corp. to Extend Period to Consummate Initial Business Combination

JUPITER, FL / ACCESSWIRE / March 6, 2023 / Jupiter Wellness Acquisition Corp. (NASDAQ:JWAC), a publicly traded special purpose acquisition company, announced today that the Company intends to extend the period it has to consummate its initial business combination by three months from March 8, 2023, to June 8, 2023…
bubmag
March 6, 2023
Insignia Systems, Inc. Announces Fourth Quarter And Full Year 2022 Financial Results NASDAQ

Insignia Systems, Inc. Announces Fourth Quarter And Full Year 2022 Financial Results

MINNEAPOLIS, MN / ACCESSWIRE / March 6, 2023 / Insignia Systems, Inc. (Nasdaq:ISIG) ("Insignia") today reported financial results for the fourth quarter ("Q4") and the full year ended December 31, 2022. Overview Q4 2022 net sales were $4.5 million, compared to $4.5 million in Q4 2021.Q4 2022 operating loss was…
bubmag
March 6, 2023
Society Pass Inc. (Nasdaq: SOPA)’s NusaTrip Continues Expansion in Southeast Asia (SEA), Extending Services to Vietnam NASDAQ

Society Pass Inc. (Nasdaq: SOPA)’s NusaTrip Continues Expansion in Southeast Asia (SEA), Extending Services to Vietnam

SINGAPORE, Mar 6, 2023 - (ACN Newswire) - NusaTrip, Indonesia's first IATA-certified online travel agency (OTA) and the travel vertical of Nasdaq-listed Society Pass Incorporated (SOPA), today announces the opening of an office in Ho Chi Minh City, Vietnam, representing its third SEA regional office outside of Jakarta, following the…
bubmag
March 6, 2023
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer’s Disease NASDAQ

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease - Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional…
bubmag
March 6, 2023
Zentek Clarifies Certain Disclosure NASDAQ

Zentek Clarifies Certain Disclosure

GUELPH, ON / ACCESSWIRE / March 3, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, announces that, pursuant to a review by the Ontario Securities Commission (the "OSC") of the Company's continuous disclosure, at the OSC's request, the Company has removed from…
bubmag
March 3, 2023
Ranger Oil Corporation Declares Quarterly Cash Dividend and Schedules Fourth Quarter and Full-Year 2022 Earnings Release Date NASDAQ

Ranger Oil Corporation Declares Quarterly Cash Dividend and Schedules Fourth Quarter and Full-Year 2022 Earnings Release Date

HOUSTON, TX / ACCESSWIRE / March 3, 2023 / Ranger Oil Corporation ("Ranger Oil" or the "Company") (NASDAQ:ROCC) today announced that its Board of Directors (the "Board") declared a quarterly cash dividend of $0.075 per share and also announced that it will release Fourth Quarter and Full-Year 2022 earnings after…
bubmag
March 3, 2023